Company intelligence / Profile preview

AlbaJuna Therapeutics

Badalona, Catalonia, Spain

Ownership: Private
Development stage: Other

Overview

AlbaJuna Therapeutics is developing multifunctional monoclonal antibodies for HIV treatment, with in vitro results demonstrating antibodies 100 times more potent than existing candidates at neutralizing HIV and activating natural killer cells to destroy infected cells. Clinical development is ongoing, with promising pre-clinical data, but no clinical results have been reported yet.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

GrifolsIrsiCaixaCan Ruti Campus teams

Beyond the preview

Go deeper on AlbaJuna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlbaJuna Therapeutics.

Explore the full profile